The Europe genetic testing market is projected to register a CAGR of 10.04% during the forecast period, 2022-2030, garnering a revenue of $8274.6 million by 2030.

EUROPE GENETIC TESTING MARKET FORECAST 2022-2030

Europe Genetic Testing Market by Type (Prenatal and Newborn Testing, Diagnostic Testing, Predictive & Pre symptomatic Testing, Carrier Testing, Pharmacogenomic Testing, Other Types) Market by Technology (Molecular Testing, Cytogenetic Testing, Biochemical Testing) Market by Application (Genetic Disease Diagnosis, Cancer Diagnosis, Cardiovascular Disease Diagnosis, Other Applications) Market by Disease (Cancer, Cystic Fibrosis, Huntington’s Disease, Sickle Cell Anaemia, Duchenne Muscular Dystrophy, Alzheimer’s Disease, Rare Diseases, Thalassemia, Other Diseases) by Geography

Request free sample

The Europe genetic testing market is projected to register a CAGR of 10.04% during the forecast period, 2022-2030, garnering a revenue of $8274.6 million by 2030.

Europe has lucrative market prospects with high living standards and per capita income. As a result, essential health services are affordable, given the high purchasing power. Also, the region has a well-established healthcare system, with governments subsidizing the healthcare industry. For instance, healthcare expenditure almost doubled between 2002 and 2019.

Europe Genetic Testing Market

To know more about this report, request a free sample copy

The Europe genetic testing market growth evaluation includes the assessment of Spain, Italy, Nordic Countries, Russia, the United Kingdom, France, Germany, and Rest of Europe. The United Kingdom boasts of well-developed healthcare systems. In 2020, the healthcare expenditure recorded an increase of 20% in nominal terms compared to 2019. Also, the National Healthcare Services (NHS) offers free healthcare to UK citizens. NHS medical genetics services provide cover for both children and adults. These are conducted in two parts, laboratory genetics services and clinical genetics services. The former entails scientists undertaking a range of blood and genetic tests. The latter includes genetic counselors and doctors diagnosing genetic conditions and assessing genetic condition inheritance or development risks.

Germany is the third-largest medical technology market globally. Its medical device market is one of the most profitable markets, accounting for 25.6% of the total European market. Also, the country has a strong healthcare system in terms of trained staff, hospital beds, and infrastructure. In addition, the Berlin (Germany) based IMMD is a leading laboratory that offers tests for genetic diseases to clinicians, physicians, and the general public.

Whereas in countries like Switzerland, there have been increasing investments in biotechnology companies. Also, the western Switzerland region called the ‘Health Valley,’ ranks second in the country in terms of financing private biotech companies. In addition, the life sciences sector in 2020 recorded an export value of CHF 99.09 billion, constituting a 44% share of total Swiss exports.

The report scope of the Europe genetic testing market includes the segmentation assessment of type, application, technology, and disease. The application segment is further sub-categorized to cardiovascular disease diagnosis, genetic disease diagnosis, cancer diagnosis, and other applications. Cancer diagnosis is gaining traction as the dominating application in the market.

Cancer is not inherited, but genes influence certain types like prostate, colorectal, ovarian, and breast cancers, and can run in families. BRCA1 and BRCA2 are the genes that increase the cancer risk upon alteration. For instance, a variant BRCA gene increases a woman’s chance of developing ovarian and breast cancer. On the other hand, it raises the risk of prostate cancer and male breast cancer. Additionally, researchers have identified 100 more gene variants that elevate the risk of ovarian, prostate, and breast cancers.

Some of the leading companies in the Europe genetic testing market include Illumina Inc, Eurofins Scientific, Myriad Genetics Inc, Luminex Corporation, etc.

Eurofins Scientific SE provides laboratory and analytical services globally. The company’s portfolio includes around 200,000 analytical methods for assessing the purity, traceability, origin, authenticity, composition, identity, and safety of biological substances and products. Its clients include clinical diagnostics, environmental, food, and pharmaceutical sectors. The company operates around 800 laboratories in 50 countries, with headquarters in Luxembourg City, Luxembourg

Further, the Eurofins BioPharma Product Testing network of laboratories provides expertise for preparing and characterizing a wide variety of insect and mammalian cell banks.

Report Synopsis

Report ScopeDetails
Market Forecast Years2022-2030
Base Year2021
Market Historical Years2018-2021
Forecast UnitsRevenue ($ Million)
Segments AnalyzedDisease, Application, Technology, Type
Countries AnalyzedSpain, Italy, Nordic Countries, Russia, the United Kingdom, France, Germany, and Rest of Europe
Companies Analyzed

23&Me Inc, Abbott Laboratories, BGI Group, Bio-Rad Laboratories, CSL Limited, Decode Genetics, ELITech Group, Eurofins Scientific, Illumina Inc, Luminex Corporation, Myriad Genetics Inc, PerkinElmer Inc, Qiagen, Quest Diagnostics Inc, and Roche Diagnostics Inc

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    1. RESEARCH SCOPE & METHODOLOGY
      • STUDY OBJECTIVES
      • SCOPE OF STUDY
      • METHODOLOGY
      • ASSUMPTIONS & LIMITATIONS
    2. EXECUTIVE SUMMARY
      • MARKET SIZE & ESTIMATES
      • MARKET OVERVIEW
    3. MARKET DYNAMICS
      • KEY DRIVERS
        • ADVANCEMENTS IN BIOTECHNOLOGY
        • GROWTH IN PRENATAL TESTING
        • RISE IN DIRECT-TO-CONSUMER GENETIC TESTING
        • GENETIC TESTING HELPS IN DETERMINING MEDICATION DOSAGE
      • KEY RESTRAINTS
        • EXPENSIVE COST OF TREATMENT
        • GOVERNMENT REGULATION AND LEGISLATION
    1. KEY ANALYTICS
      • IMPACT OF COVID-19 ON GENETIC TESTING MARKET
      • KEY MARKET TRENDS
      • PORTER’S FIVE FORCES ANALYSIS
        • BUYERS POWER
        • SUPPLIERS POWER
        • SUBSTITUTION
        • NEW ENTRANTS
        • INDUSTRY RIVALRY
      • OPPORTUNITY MATRIX
      • VENDOR LANDSCAPE
      • VALUE CHAIN ANALYSIS
      • KEY BUYING CRITERIA
      • REGULATORY FRAMEWORK
    2. MARKET BY TYPE
      • PRENATAL AND NEWBORN TESTING
      • DIAGNOSTIC TESTING
      • PREDICTIVE & PRESYMPTOMATIC TESTING
      • CARRIER TESTING
      • PHARMACOGENOMIC TESTING
      • OTHER TYPES
    3. MARKET BY TECHNOLOGY
      • MOLECULAR TESTING
      • CYTOGENETIC TESTING
      • BIOCHEMICAL TESTING
    4. MARKET BY APPLICATION
      • GENETIC DISEASE DIAGNOSIS
      • CANCER DIAGNOSIS
      • CARDIOVASCULAR DISEASE DIAGNOSIS
      • OTHER APPLICATIONS
    5. MARKET BY DISEASE
      • CANCER
      • CYSTIC FIBROSIS
      • HUNTINGTON’S DISEASE
      • SICKLE CELL ANAEMIA
      • DUCHENNE MUSCULAR DYSTROPHY
      • ALZHEIMER’S DISEASE
      • RARE DISEASES
      • THALASSEMIA
      • OTHER DISEASES
    6. GEOGRAPHICAL ANALYSIS
      • EUROPE
        • MARKET SIZE & ESTIMATES
        • KEY GROWTH ENABLERS
        • KEY CHALLENGES
        • KEY PLAYERS
        • COUNTRY ANALYSIS
          • UNITED KINGDOM
          • GERMANY
          • FRANCE
          • SPAIN
          • ITALY
          • RUSSIA
          • NORDIC COUNTRIES
          • REST OF EUROPE
    1. COMPETITIVE LANDSCAPE
      • KEY STRATEGIC DEVELOPMENTS
        • MERGERS & ACQUISITIONS
        • PRODUCT LAUNCHES & DEVELOPMENTS
        • PARTNERSHIPS & AGREEMENTS
        • BUSINESS EXPANSIONS & DIVESTITURES
      • COMPANY PROFILES
        • 23&ME INC
        • ABBOTT LABORATORIES
        • BGI GROUP
        • BIO-RAD LABORATORIES
        • CSL LIMITED
        • DECODE GENETICS
        • ELITECH GROUP
        • EUROFINS SCIENTIFIC
        • ILLUMINA INC
        • LUMINEX CORPORATION
        • MYRIAD GENETICS INC
        • PERKINELMER INC
        • QIAGEN
        • QUEST DIAGNOSTICS INC
        • ROCHE DIAGNOSTICS INC

    LIST OF TABLES

    TABLE 1: MARKET SNAPSHOT – GENETIC TESTING

    TABLE 2: REGULATORY FRAMEWORK

    TABLE 3: EUROPE GENETIC TESTING MARKET, BY TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 4: EUROPE GENETIC TESTING MARKET, BY TYPE, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 5: EUROPE GENETIC TESTING MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 6: EUROPE GENETIC TESTING MARKET, BY TECHNOLOGY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 7: EUROPE GENETIC TESTING MARKET, BY APPLICATION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 8: EUROPE GENETIC TESTING MARKET, BY APPLICATION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 9: EUROPE GENETIC TESTING MARKET, BY DISEASE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 10: EUROPE GENETIC TESTING MARKET, BY DISEASE, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 11: EUROPE GENETIC TESTING MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 12: EUROPE GENETIC TESTING MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 13: LEADING PLAYERS OPERATING IN EUROPE GENETIC TESTING MARKET

    TABLE 14: LIST OF MERGERS & ACQUISITIONS

    TABLE 15: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

    TABLE 16: LIST OF PARTNERSHIPS & AGREEMENTS

    TABLE 17: LIST OF BUSINESS EXPANSIONS & DIVESTITURES                            

    LIST OF FIGURES

    FIGURE 1: KEY MARKET TRENDS

    FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

    FIGURE 3: OPPORTUNITY MATRIX

    FIGURE 4: VENDOR LANDSCAPE

    FIGURE 5: VALUE CHAIN ANALYSIS

    FIGURE 6: EUROPE GENETIC TESTING MARKET, GROWTH POTENTIAL, BY TYPE, IN 2021

    FIGURE 7: EUROPE GENETIC TESTING MARKET, BY PRENATAL AND NEWBORN TESTING GENETIC TESTING, 2022-2030 (IN $ MILLION)

    FIGURE 8: EUROPE GENETIC TESTING MARKET, BY DIAGNOSTIC TESTING, 2022-2030 (IN $ MILLION)

    FIGURE 9: EUROPE CARRIER TESTING MARKET, BY CARRIER TESTING, 2022-2030 (IN $ MILLION)

    FIGURE 10: EUROPE GENETIC TESTING MARKET, BY PHARMACOGENOMIC TESTING, 2022-2030 (IN $ MILLION)

    FIGURE 11: EUROPE GENETIC TESTING MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2021

    FIGURE 12: EUROPE GENETIC TESTING MARKET, BY MOLECULAR TESTING, 2022-2030 (IN $ MILLION)

    FIGURE 13: EUROPE GENETIC TESTING MARKET, BY CYTOGENETIC TESTING, 2022-2030 (IN $ MILLION)

    FIGURE 14: EUROPE GENETIC TESTING MARKET, BY BIOCHEMICAL TESTING, 2022-2030 (IN $ MILLION)

    FIGURE 15: EUROPE GENETIC TESTING MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2021

    FIGURE 16: EUROPE GENETIC TESTING MARKET, BY GENETIC DISEASE DIAGNOSIS, 2022-2030 (IN $ MILLION)

    FIGURE 17: EUROPE GENETIC TESTING MARKET, BY CANCER DIAGNOSIS, 2022-2030 (IN $ MILLION)

    FIGURE 18: EUROPE GENETIC TESTING MARKET, BY CARDIOVASCULAR DISEASES DIAGNOSIS, 2022-2030 (IN $ MILLION)

    FIGURE 19: EUROPE GENETIC TESTING MARKET, BY OTHER APPLICATIONS, 2022-2030 (IN $ MILLION)

    FIGURE 20: EUROPE GENETIC TESTING MARKET, GROWTH POTENTIAL, BY DISEASE, IN 2021

    FIGURE 21: EUROPE GENETIC TESTING MARKET, BY CANCER, 2022-2030 (IN $ MILLION)

    FIGURE 22: EUROPE GENETIC TESTING MARKET, BY CYSTIC FIBROSIS, 2022-2030 (IN $ MILLION)

    FIGURE 23: EUROPE GENETIC TESTING MARKET, BY HUNTINGTON’S DISEASE, 2022-2030 (IN $ MILLION)

    FIGURE 24: EUROPE GENETIC TESTING MARKET, SICKLE CELL ANEMIA, 2022-2030 (IN $ MILLION)

    FIGURE 25: EUROPE GENETIC TESTING MARKET, BY DUCHENNE MUSCULAR DYSTROPHY, 2022-2030 (IN $ MILLION)

    FIGURE 26: EUROPE GENETIC TESTING MARKET, BY ALZHEIMER’S DISEASE, 2022-2030 (IN $ MILLION)

    FIGURE 27: EUROPE GENETIC TESTING MARKET, BY RARE DISEASES, 2022-2030 (IN $ MILLION)

    FIGURE 28: EUROPE GENETIC TESTING MARKET, BY THALASSEMIA, 2022-2030 (IN $ MILLION)

    FIGURE 29: EUROPE GENETIC TESTING MARKET, BY OTHER DISEASES, 2022-2030 (IN $ MILLION)

    FIGURE 30: EUROPE GENETIC TESTING MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

    FIGURE 31: UNITED KINGDOM GENETIC TESTING MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 32: GERMANY GENETIC TESTING MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 33: FRANCE GENETIC TESTING MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 34: SPAIN GENETIC TESTING MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 35: ITALY GENETIC TESTING MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 36: RUSSIA GENETIC TESTING MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 37: NORDIC COUNTRIES GENETIC TESTING MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 38: REST OF EUROPE GENETIC TESTING MARKET, 2022-2030 (IN $ MILLION)       

    1. GEOGRAPHICAL ANALYSIS
      • EUROPE
        • MARKET SIZE & ESTIMATES
        • KEY GROWTH ENABLERS
        • KEY CHALLENGES
        • KEY PLAYERS
        • COUNTRY ANALYSIS
          • UNITED KINGDOM
          • GERMANY
          • FRANCE
          • SPAIN
          • ITALY
          • RUSSIA
          • NORDIC COUNTRIES
          • REST OF EUROPE
    1. MARKET BY TYPE
      • PRENATAL AND NEWBORN TESTING
      • DIAGNOSTIC TESTING
      • PREDICTIVE & PRESYMPTOMATIC TESTING
      • CARRIER TESTING
      • PHARMACOGENOMIC TESTING
      • OTHER TYPES
    2. MARKET BY TECHNOLOGY
      • MOLECULAR TESTING
      • CYTOGENETIC TESTING
      • BIOCHEMICAL TESTING
    3. MARKET BY APPLICATION
      • GENETIC DISEASE DIAGNOSIS
      • CANCER DIAGNOSIS
      • CARDIOVASCULAR DISEASE DIAGNOSIS
      • OTHER APPLICATIONS
    4. MARKET BY DISEASE
      • CANCER
      • CYSTIC FIBROSIS
      • HUNTINGTON’S DISEASE
      • SICKLE CELL ANAEMIA
      • DUCHENNE MUSCULAR DYSTROPHY
      • ALZHEIMER’S DISEASE
      • RARE DISEASES
      • THALASSEMIA
      • OTHER DISEASES

    To request a free sample copy of this report, please complete the form below :

    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

      Choose License Type